Current Headlines

31. Streamlining Genotyping With The INTEGRA VOYAGER Pipette 10/2/2026

    The Robling Lab at Indiana University School of Medicine uses liquid handling solutions from INTEGRA Biosciences to aid its vital research into bone development and homeostasis.

32. Streamlining Cell Cultures With INTEGRA's VACUSAFE To Advance Respiratory Health Research 10/2/2026

    Researchers at the University of Technology Sydney (UTS), Australia, rely on the VACUBOY vacuum hand operator and VACUSAFE aspiration system from INTEGRA Biosciences to aid their research into respiratory health.

33. INTEGRA Clean-Up Week: Employees Send A Clear Signal For Sustainability And Responsibility 10/2/2026

    INTEGRA Biosciences carried out a cross-site Clean-Up Week in September 2026 at its main sites in Zizers, Switzerland, and Hudson/Merrimack, US. Over the course of a week, employees contributed to a more organized work environment, a more conscious use of resources, and a cleaner environment, both within the company and in the areas surrounding the sites.

34. INTEGRA Helps To Streamline CRISPR Workflows, From Editing To Analysis 10/2/2026

    INTEGRA Biosciences has collaborated with biotechnology companies DropGenie and QUiCKR Bio to create efficient automated solutions for CRISPR editing and analysis.

35. INTEGRA Biosciences Launches Its Most Sustainable ECO Racks Yet 10/2/2026

    INTEGRA Biosciences has introduced newly evolved ECO rack GRIPTIPS^® pipette tips, which are now translucent rather than fully pigmented, making the recycled material more suitable for a wider range of new products.

36. INTEGRA Launches New Eco-Friendly ACT Ecolabel Certified AUTO Rack GRIPTIPS® For Benchtop Systems 10/2/2026

    INTEGRA Biosciences has launched the My Green Lab^® ACT^® Ecolabel certified AUTO rack GRIPTIPS^® pipette tips for its benchtop liquid handling platforms.

37. DaltonTx, The Decision Engine For Drug Discovery, Launches Advanced AI-Powered Antibody Discovery Platform 10/1/2026

    DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform.

38. Talus Bio Launches Ptarmigan-1, The First Structure-Free AI Model For Proteome-Wide Drug Discovery 10/1/2026

    Talus Bioscience, Inc. (“Talus Bio”), an AI-native therapeutics company, today released Ptarmigan-1, the first structure-free model that can accurately predict small molecule binding sites across the entire human proteome, including proteins too disordered for traditional 3D modeling to resolve.

39. Rakovina Therapeutics Partners With Boston-Based Celvion Therapeutics To Leverage AI And Real-World Clinical Data For Precision Cancer Drug Development 10/1/2026

    Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EMphora™ artificial intelligence platform to identify novel precision medicine strategies designed to accelerate the development of Rakovina’s ATR inhibitor program.

40. Piramal Pharma Solutions And NP2 To Complete Cyclophosphamide Development Phase Next Month 9/30/2026

    Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.